Gd2O3 nanoparticles as a positive MRI contrast agent for cell uptake

Author(s):  
N. Riyahi-Alam ◽  
J. Behrouzkia ◽  
S. Haghgoo ◽  
A Seifalian ◽  
R Zohdi Aghdam. ◽  
...  
2013 ◽  
Vol 06 (01) ◽  
pp. 1250052 ◽  
Author(s):  
YANG TIAN ◽  
BINBIN YU ◽  
HONG-YU YANG ◽  
JI LIAO

Bifunctional nanospheres of silica encapsulating Fe3O4 and LaF3 : Eu nanoparticles were synthesized in a reverse microemulsion solution. The nanospheres were perfectly monodispersed with a small diameter of 20 nm. The composition of the bifunctional nanospheres was confirmed by powder X-ray diffraction. Their magnetic and luminescent properties were measured at room temperature. The relaxation efficiency and T2-weighted images showed the high-performance for the product as a resonance imaging contrast agent. In addition, a qualitative cell uptake in human cervical cancer HeLa cells demonstrated that the SFLE nanospheres were efficiently up-taken into cytosol. Taken together, these findings suggest that the SiO2 / Fe3O4 - LaF3 : Eu 3+ nanospheres are good luminescence probes for bio-imaging.


2010 ◽  
Vol 37 (6Part5) ◽  
pp. 3135-3136
Author(s):  
N Riyahi-Alam ◽  
Z Behrouzkia ◽  
A Seifalian ◽  
S Haghgoo

Molecules ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 1477 ◽  
Author(s):  
Xuanrong Sun ◽  
Yue Cai ◽  
Zhuomin Xu ◽  
Dabu Zhu

We developed a tumor-targeted contrast agent based on linear polylysine (PLL) by conjugating a small molecular imaging agent, fluorescent molecule and targeting agent amino phenylboronic acid onto the amino groups of polylysine, which can specifically target monosaccharide sialic acid residues overexpressing on the surface of tumor cell membranes. Further, 3,4,5,6-Tetrahydrophthalic anhydride (DCA) was attached to the free amino groups of the polylysine to change to a negative charge at physiology pH to lower the cytotoxicity, but it soon regenerated to a positive charge again once reaching the acidic intratumoral environment and therefore increased cell uptake. Laser confocal microscopy images showed that most of the polymeric contrast agents were bound to the cancer cell membrane. Moreover, the tumor targeting contrast agent showed the same magnetic resonance imaging (MRI) contrasting performance in vitro as the small molecule contrast agent used in clinic, which made it a promising tumor-targeting polymeric contrast agent for cancer diagnosis.


RSC Advances ◽  
2019 ◽  
Vol 9 (25) ◽  
pp. 14051-14059
Author(s):  
Abdulrahman Ahmed Mahmood ◽  
Jianqi Zhang ◽  
Rufang Liao ◽  
Xiwei Pan ◽  
Dan Xu ◽  
...  

The acid-responsive pHLIP modified SPION as an MRI contrast agent for liver cancer diagnosis requires the validation of both the tumor-specific enhancement and a safe profile in cirrhosis.


Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1235
Author(s):  
Xiaohui Nan ◽  
Wenjia Lai ◽  
Dan Li ◽  
Jiesheng Tian ◽  
Zhiyuan Hu ◽  
...  

Derived from magnetotactic bacteria (MTB), magnetosomes consist of magnetite crystals enclosed within a lipid bilayer membrane and are known to possess advantages over artificially synthesized nanoparticles because of the narrow size distribution, uniform morphology, high purity and crystallinity, single magnetic domain, good biocompatibility, and easy surface modification. These unique properties have increasingly attracted researchers to apply bacterial magnetosomes (BMs) in the fields of biology and medicine as MRI imaging contrast agents. Due to the concern of biosafety, a long-term follow-up of the distribution and clearance of BMs after entering the body is necessary. In this study, we tracked changes of BMs in major organs of mice up to 135 days after intravenous injection using a combination of several techniques. We not only confirmed the liver as the well-known targeted organs of BMs, but also found that BMs accumulated in the spleen. Besides, two major elimination paths, as well as the approximate length of time for BMs to be cleared from the mice, were revealed. Together, the results not only confirm that BMs have high biocompatibility, but also provide a long-term in-vivo assessment which may further help to forward the clinical applications of BMs as an MRI contrast agent.


Author(s):  
Juliette Moreau ◽  
Maité Callewaert ◽  
Volodymyr Malytskyi ◽  
Céline Henoumont ◽  
Sorina N. Voicu ◽  
...  

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.


Sign in / Sign up

Export Citation Format

Share Document